Mektovi (binimetinib) is a kinase inhibitor prescribed for the treatment of unresectable or metastatic melanoma with a specific mutation (BRAF V600E or V600K). It works by blocking the activity of MEK1 and MEK2 proteins, which are part of the MAPK/ERK pathway that promotes cancer cell growth and survival. Mektovi is typically used in combination with another medication, encorafenib, to improve treatment effectiveness. Taken orally twice daily, Mektovi may cause side effects including rash, diarrhea, fatigue, and elevated liver enzymes. Regular monitoring by healthcare providers is essential during therapy.